Zealand Pharma, Novo Nordisk Ink Licensing Pact For Diabetes Drug

Zealand Pharma A/S (NASDAQ: ZEAL) has entered into a global license and development agreement with Novo Nordisk A/S (NYSE: NVO) to commercialize Zegalogue (dasiglucagon) for injection.